Tag: Ipsen

New Jersey Carcinoid/Neuroendocrine Cancer Conference in October, Registration Closing Soon

Two of the country’s leading carcinoid and neuroendocrine cancer specialists, a cardiologist with expertise in carcinoid heart disease, a registered dietitian who works regularly with the NET community, and a nurse practitioner with extensive…

New Survey for the Carcinoid and Neuroendocrine Tumor Community

The Carcinoid Cancer Foundation is always looking at ways of improving content and services available to people living with carcinoid cancer and other neuroendocrine tumors and we are working with a pharmaceutical partner, Ipsen, to better understand…

In Memoriam: Edda Gomez-Panzani, MD

It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

• PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society

9 News Items for the Carcinoid and Neuroendocrine Cancer Community

1. Groundbreaking research from Novartis as they develop drugs that train our immune system to detect and fight tumors. Dr. Glenn Dranoff, a cancer vaccine expert, will lead Novartis’ new research efforts in the area of immuno-oncology. Read …

CNETS Singapore Presents New Webinar Series Featuring Neuroendocrine Cancer Experts

The Carcinoid & Neuroendocrine Tumor Society (CNETS) of Singapore is embarking on a series of webinars on various topics related to the diagnosis and treatment of neuroendocrine cancers. With the support of a grant from Ipsen Biopharmaceuticals…

10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

Breaking News: US FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors

December 16, 2014: The US Food and Drug Administration (FDA) today approved “lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic…

10 Highlights of the Year 2012 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2012, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)       NET Cancer Day, November …

Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial

Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel),  a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …